These free open-world games offer vast and beautiful open worlds, great exploration, loads of content; there's almost no catch.

Patient outcomes in advanced renal cell carcinoma (RCC) remain poor, with five-year survival rates ranging from ~10% to 30%. Early projections of therapeutic outcomes could optimize precision medicine ...

The DUO-O trial showed significant improvement in progression-free survival with Imfinzi, Avastin, and Lynparza, but no significant overall survival benefit. The study was a double-blind, multicenter ...

– Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, in a post-CDK inhibitor setting, compared with ...

Patients with estrogen-receptor-positive HER-2-negative advanced breast cancer showed significantly improved progression-free survival when treated with an oral combination regimen that includes ...

6-month progression-free survival (PFS) of 50% in the higher 15 mg/kg dose cohort compares favorably to historical PD-(L)1 refractory settings – All clinical responses, including a complete response, ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive results from the Phase III evERA study evaluating ...

Kairos Pharma Announces Positive Interim Efficacy Analysis of Phase 2 Trial of ENV105 in Advanced Prostate Cancer with Median Progression Free Survival of Over One Year Interim efficacy analysis ...

Contact: Chris Martin, MPH IASLC Media Relations [email protected] (Barcelona, Spain September 7, 2025, 10:45 a.m. CEST / UTC +2) – New results from the ACROSS 2 Phase III trial demonstrate ...

Adding ivonescimab, a first-in-class bispecific antibody targeting both PD-1 and VEGF, to chemotherapy significantly prolonged progression-free survival (PFS) compared to chemotherapy alone in ...

(Barcelona, Spain September 7, 2025, 10:45 a.m. CEST / UTC +2) — Adding ivonescimab, a first-in-class bispecific antibody targeting both PD-1 and VEGF, to chemotherapy significantly prolonged ...

Patients treated with Cylembio (imsapepimut and etimupepimut, adjuvanted) plus pembrolizumab achieved improvement in progression free survival (PFS) compared to patients treated with pembrolizumab ...